Treatment with Ang1 and Ang2 inhibitors modulates the phenotype of human tumor cells
| A. OV 17-1 | ||||||||
| HLA-A2 | CEA | MUC-1 | CD54 | Calreticulin | CD95 | Trail-R1 | Trail-R2 | |
| % (MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | |
| Control | 99.4(34250) | 40.7(731) | 55.9(1170) | 93.8(16581) | 3.5(431) | 57.2(691) | 27.4(604) | 10.1(93) |
| mL4-3 + L1-7(N) | 99.1(34180) | 40.0(872) | 59.0(1124) | 97.0(23584) | 3.7(429) | 65.3(813) | 33.7(750) | 10.1(107) |
| B. MDA-MB-231 | ||||||||
| HLA-A2 | CEA | MUC-1 | CD54 | Calreticulin | CD95 | Trail-R1 | Trail-R2 | |
| % (MFI) | % (MFI) | %(MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | % (MFI) | |
| Control | 98.7(62083) | 40.2(671) | 56.0(2268) | 97.9(30985) | 10.6(377) | 35.1(438) | 44.0(775) | 35.1(367) |
| mL4-3 + L1-7(N) | 99.1(60495) | 43.7(666) | 59.4(2670) | 99.1(35652) | 15.9(428) | 41.2(493) | 48.7(797) | 30.5(292) |
The human ovarian cancer cell line OV17-1 (A), and human breast cancer cell line MDA-MB-231 (B) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or control (human IgG1-Fc at 26 μg/mL) for 3 days
Cells were then harvested and analyzed by flow cytometry for expression of surface markers reported to be involved in CTL lysis (HLA-A2, CEA, MUC-1, ICAM-1, calreticulin, Fas, Trail-R1 and Trail-R2). Data indicate percentage of positive cells; MFI is in parentheses. Gating was performed using isotype controls Bold values indicate marker upregulation of > 10 % in percentage or MFI compared to controls